The FDA CDER/CBER Rare Disease Evidence Principles Approval Process

In a recent communication from the United States Food and Drug Administration’s (US FDA) Rare Disease Innovation Hub1, the general framework of a proposed process for facilitating approval of drugs to treat rare diseases (termed the Rare Disease Evidence Principles, or RDEP) was unveiled.